These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11267991)

  • 41. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutation analysis of a Mauritian hereditary breast cancer family reveals the BRCA2 6503deITT mutation previously found to recur in different ethnic populations.
    Khittoo G; Manning A; Mustun H; Appadoo J; Venkatasamy S; Fagoonee I; Ghadirian P; Tonin PN
    Hum Hered; 2001; 52(1):55-8. PubMed ID: 11359068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
    Santarosa M; Dolcetti R; Magri MD; Crivellari D; Tibiletti MG; Gallo A; Tumolo S; Della Puppa L; Furlan D; Boiocchi M; Viel A
    Int J Cancer; 1999 Sep; 83(1):5-9. PubMed ID: 10449599
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease.
    Haraldsson K; Loman N; Zhang QX; Johannsson O; Olsson H; Borg A
    Cancer Res; 1998 Apr; 58(7):1367-71. PubMed ID: 9537231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Laboratory identification of hereditary risk of breast and ovarian cancer.
    Frank TS
    Curr Opin Biotechnol; 1999 Jun; 10(3):289-94. PubMed ID: 10361081
    [No Abstract]   [Full Text] [Related]  

  • 47. BRCA2 germline mutations in familial pancreatic carcinoma.
    Hahn SA; Greenhalf B; Ellis I; Sina-Frey M; Rieder H; Korte B; Gerdes B; Kress R; Ziegler A; Raeburn JA; Campra D; Grützmann R; Rehder H; Rothmund M; Schmiegel W; Neoptolemos JP; Bartsch DK
    J Natl Cancer Inst; 2003 Feb; 95(3):214-21. PubMed ID: 12569143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Constitutional genomic instability with inversions, duplications, and amplifications in 9p23-24 in BRCA2 mutation carriers.
    Savelyeva L; Claas A; Matzner I; Schlag P; Hofmann W; Scherneck S; Weber B; Schwab M
    Cancer Res; 2001 Jul; 61(13):5179-85. PubMed ID: 11431357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PCR-SSCP-HDX analysis of pooled DNA for more rapid detection of germline mutations in large genes. The BRCA1 example.
    Kozłowski P; Sobczak K; Napierała M; Woźniak M; Czarny J; Włodzimierz J; Kryzosiak J
    Nucleic Acids Res; 1996 Mar; 24(6):1177-8. PubMed ID: 8604357
    [No Abstract]   [Full Text] [Related]  

  • 50. Contribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany.
    Hamann U; Liu X; Lange S; Ulmer HU; Benner A; Scott RJ
    J Med Genet; 2002 Mar; 39(3):E12. PubMed ID: 11897832
    [No Abstract]   [Full Text] [Related]  

  • 51. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.
    Thorlacius S; Olafsdottir G; Tryggvadottir L; Neuhausen S; Jonasson JG; Tavtigian SV; Tulinius H; Ogmundsdottir HM; Eyfjörd JE
    Nat Genet; 1996 May; 13(1):117-9. PubMed ID: 8673089
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRCA2 hereditary breast cancer pathophenotype.
    Marcus JN; Watson P; Page DL; Narod SA; Tonin P; Lenoir GM; Serova O; Lynch HT
    Breast Cancer Res Treat; 1997 Jul; 44(3):275-7. PubMed ID: 9266108
    [No Abstract]   [Full Text] [Related]  

  • 54. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
    Goshen R; Chu W; Elit L; Pal T; Hakimi J; Ackerman I; Fyles A; Mitchell M; Narod SA
    Gynecol Oncol; 2000 Dec; 79(3):477-81. PubMed ID: 11104623
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany.
    Kiechle M; Gross E; Schwarz-Boeger U; Pfisterer J; Jonat W; Gerber WD; Albacht B; Fischer B; Schlegelberger B; Arnold N
    Hum Mutat; 2000 Dec; 16(6):529-30. PubMed ID: 11102986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BRCA1/BRCA2 in breast-conserving therapy.
    Turner BC; Glazer PM; Haffty BG
    J Clin Oncol; 1999 Nov; 17(11):3689. PubMed ID: 10550169
    [No Abstract]   [Full Text] [Related]  

  • 57. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
    Sarantaus L; Auranen A; Nevanlinna H
    Int J Oncol; 2001 Apr; 18(4):831-5. PubMed ID: 11251181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum.
    Haber DA
    J Clin Oncol; 1999 Nov; 17(11):3367-70. PubMed ID: 10550129
    [No Abstract]   [Full Text] [Related]  

  • 59. BRCA1 mutations in a population-based sample of young women with breast cancer.
    Langston AA; Malone KE; Thompson JD; Daling JR; Ostrander EA
    N Engl J Med; 1996 Jan; 334(3):137-42. PubMed ID: 8531967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genome-wide views of cancer.
    Golub TR
    N Engl J Med; 2001 Feb; 344(8):601-2. PubMed ID: 11207357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.